SCHEMBL2567911

SCHEMBL2567911

CC(C)(C)OC(=O)CN(CCN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(CCCCN)C(=O)OC(C)(C)C)CC(=O)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 3/20 0.33
EPOR P19235 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543850 1.00 CPB2 (0.33) CPB2EPOR
SCHEMBL7601678 0.96 CPB2 (0.33) CPB2EPOR
SCHEMBL6232568 0.93 EPOR (0.40) CPB2EPOR
SCHEMBL7881945 0.90 CPB2 (0.36) CPB2EPOR
SCHEMBL6232124 0.89 EPOR (0.40) CPB2EPOR
SCHEMBL4537445 0.88 CPB2 (0.37) CPB2EPOR
SCHEMBL896853 0.88 CPB2 (0.37) CPB2EPOR
SCHEMBL4564930 0.82 TDP1 (0.31)
SCHEMBL14345486 0.82 TDP1 (0.31)
SCHEMBL5032518 0.82 TDP1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9907637-B2 Modular bioresorbable or biomedical, biologically active supramolecular materials SUPRAPOLIX B.V. (NL) 2018-03-06 US disclosed
US-20160228229-A1 MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS SUPRAPOLIX B.V. (NL) 2016-08-11 US disclosed
US-8883188-B2 Modular bioresorbable or biomedical, biologically active supramolecular materials SUPRAPOLIX B.V. (NL) 2014-11-11 US disclosed
US-20140234211-A1 SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS INVECTORS S.R.L. (IT) 2014-08-21 US disclosed
EP-1877113-B1 MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS SUPRAPOLIX BV (NL) 2011-11-09 EP disclosed
US-20090130172-A1 Modular Bioresorbable or Biomedical, Biologically Active Supramolecular Materials SUPRAPOLIX B.V. (NL) 2009-05-21 US disclosed
EP-1877113-A2 MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS SupraPolix B.V. (NL) 2008-01-16 EP disclosed
WO-2006118461-A2 MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS SUPRAPOLIX B. V. (NL) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234211-A1 SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS GRPR, BRS3, BID CPB2 1329/4885EPOR 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.